When malignant hyperthermia triggering agents are used, what monitoring and action is required?

• A. Monitor temperature and recognize signs and immediately initiate appropriate treatment
• B. Do nothing
• C. Increase the ambient room temperature
• D. Rely on postoperative observation

Answer: (A)

Malignant hyperthermia is a life-threatening reaction to certain anesthetic agents that demands rapid recognition and immediate treatment. The important practice during anesthesia is to continuously look for early signs, especially a sudden rise in temperature and other indicators such as a rapid increase in end-tidal CO2, tachycardia, and muscle rigidity. When these signs appear, action must be taken without delay: stop the triggering agents, administer 100% oxygen, and begin the MH treatment protocol right away with dantrolene (the first dose given promptly, typically around 2.5 mg/kg IV, with additional dosing as needed up to the recommended total). Prepare to implement cooling measures, manage metabolic acidosis and electrolyte disturbances, and support renal protection with adequate urine output. Having the anesthesia plan ready and reachable—dantrolene, cooling resources, and a team to assist—greatly improves outcomes. Choices that suggest doing nothing, warming the room, or waiting for postoperative observation would miss the urgent need to recognize early signs and treat immediately.